Mingfu Zhu
Keine laufenden Positionen mehr
Karriereverlauf von Mingfu Zhu
Ehemalige bekannte Positionen von Mingfu Zhu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
20n Bio
 20n Bio BiotechnologyHealth Technology 20n Bio is a venture-backed startup based in Malvern, PA. The company's focus is on generating protein drugs in silico with desired biophysical, functional, and pharmacological properties. The company was founded in 2021 by Mingfu Zhu and is dedicated to using artificial intelligence to design novel protein therapeutics to address unmet medical needs. | Gründer | - | - |
Panorama Medicine, Inc.
 Panorama Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Panorama Medicine, Inc. operates a drug discovery platform that integrates genomics, big data, and computing to find drugs that can treat diseases caused by errors during RNA processing. The company was founded by Yi Xing, Mingfu Zhu, and Douglas Black in 2018 and is headquartered in Philadelphia, PA. | Direktor/Vorstandsmitglied | 01.01.2018 | - |
| Vorstandsvorsitzender | 01.01.2018 | - | |
| Gründer | 01.01.2018 | - |
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Founder | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Commercial Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Panorama Medicine, Inc.
Panorama Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Panorama Medicine, Inc. operates a drug discovery platform that integrates genomics, big data, and computing to find drugs that can treat diseases caused by errors during RNA processing. The company was founded by Yi Xing, Mingfu Zhu, and Douglas Black in 2018 and is headquartered in Philadelphia, PA. | Commercial Services |
20n Bio
20n Bio BiotechnologyHealth Technology 20n Bio is a venture-backed startup based in Malvern, PA. The company's focus is on generating protein drugs in silico with desired biophysical, functional, and pharmacological properties. The company was founded in 2021 by Mingfu Zhu and is dedicated to using artificial intelligence to design novel protein therapeutics to address unmet medical needs. | Health Technology |
- Börse
- Insiders
- Mingfu Zhu
- Erfahrung
